SIGN UP TO VIEW THE FULL ARTICLE

Receive a 90-day free trial of Celltelligence and get instant access to our full offering.


EMAIL BLASTS

Curated cell therapy industry news in your inbox multiple times each week

SEARCHABLE LIBRARY

A full archive of cell therapy news, insights, and context

THE MAP

A 24/7 information center that lets you make unique connections

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.

Account Information

LEAVE THIS BLANK

By selecting this, I agree to receive emails from celltelligence.com.

Already have an account? Log in here
RETURN TO HOME
$0
Allogeneic, CAR-T, CD19

Updated Interim Results from PBCAR0191’s Ph1/2a Trial; New Details Provided for PBCAR19B Stealth CAR-T Program; Precision’s Pre-ASCO CD19 Event

Here is a brief preview of this blast: On Friday, June 4, Precision BioSciences held their PBCAR0191 CD19 virtual update event (webcast / presentation). Management reported updated results on PBCAR0191’s Ph1/2a trial in r/r NHL while providing further details on their CD19 stealth cell program (PBCAR19B). Below, Celltelligence provides insights on the effect of Precision’s enhanced lymphodepletion (eLD) regimen to improve PBCAR0191’s efficacy while comparing PBCAR0191’s dosing strategy and lymphodepletion approach with key competitor Allogene.

About The Author

The Celltelligence Team

|
Content Leads & Contributors
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.